Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press60610.17650/1994-4098-2018-14-3-48-54MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИIndividual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancerИндивидуальный подход к выбору варианта адъювантной гормональной терапии у пациенток с ранним раком молочной железыhttps://orcid.org/0000-0003-4382-5697SlonimskayaE. M.СлонимскаяЕ. М.
Russian Federation

5 Kooperativniy per., Tomsk 634050

634 009 Томск, пер. Кооперативный, 5

slonimskaya@rambler.ruhttps://orcid.org/0000-0001-8846-9636DoroshenkoA. V.ДорошенкоА. В.
Russian Federation

5 Kooperativniy per., Tomsk 634050

634 009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0002-2953-0350KazantsevaP. V.КазанцеваП. В.
Russian Federation

5 Kooperativniy per., Tomsk 634050

634 009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0003-1630-4466TarabanovskayaN. A.ТарабановскаяН. А.
Russian Federation

5 Kooperativniy per., Tomsk 634050

634 009 Томск, пер. Кооперативный, 5

VernadskyR. Yu.ВернадскийР. Ю.
Russian Federation

5 Kooperativniy per., Tomsk 634050

634 009 Томск, пер. Кооперативный, 5

Oncology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesНИИ онкологии ФГБНУ «Томский национальный исследовательский медицинский центр РАН»1610201814348541510201815102018https://ojrs.abvpress.ru/ojrs/article/view/606

Adjuvant hormone therapy is considered the gold standard of therapy for hormone receptor-positive operable breast cancer. The approach to adjuvant hormone therapy in premenopausal patients has changed significantly in recent years. This change was caused by clinical trials, which have confirmed the advantage of adding ovarian suppression to tamoxifen or aromatase inhibitors monotherapy. Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in premenopausal patients with breast cancer should be based on the assessment of risks for relapse, expected effectiveness of treatment and evaluation of drug safety.

Адъювантная гормональная терапия является общепринятым стандартом лечения для женщин с гормоноположительным операбельным раком молочной железы. В последние годы у пациенток с сохраненной менструальной функцией подход к ее проведению претерпел значительные изменения. Это связано с тем, что стали доступны новые данные клинических исследований, подтверждающие преимущество добавления овариальной супрессии к тамоксифену или при использовании ее комбинации с ингибиторами ароматазы. Индивидуальный подход к выбору адекватного объема адъювантной гормонотерапии у пациенток с раком молочной железы, находящихся в пременопаузальном периоде, должен осуществляться исходя из категорий риска развития рецидива заболевании, ожидаемой эффективности лечения и профиля безопасности препаратов.

breast cancerhormone therapyovarian suppressiongonadotropin-releasing hormone analoguestamoxifenexemestaneрак молочной железыгормональная терапияовариальная супрессияаналоги гонадотропин-рилизинг гормонатамоксифенэксеместан1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии Минздрава России», 2017. [Malignant tumors in Russia in 2015 (incidence and mortality). Eds.: A. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Moscow: P. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Radiology Center, Ministry of Health of Russia, 2017. (In Russ.)].Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии Минздрава России», 2017. [Malignant tumors in Russia in 2015 (incidence and mortality). Eds.: A. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Moscow: P. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Radiology Center, Ministry of Health of Russia, 2017. (In Russ.)].2. SEER Cancer Statistics Review, 1975–2014. N. Howlader, A.M. Noone, M. Krapcho, D. Miller , K. Bishop, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J.Feuer, K.A. Cronin (eds). Bethesda, MD: National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.SEER Cancer Statistics Review, 1975–2014. N. Howlader, A.M. Noone, M. Krapcho, D. Miller , K. Bishop, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J.Feuer, K.A. Cronin (eds). Bethesda, MD: National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.3. Lambertini M., Pinto A.C., Ameye L. et al. The prognostic performance of adjuvant! Online and Nottingham prognostic index in young breast cancer patients. Br J Cancer 2016;115:1471–8.Lambertini M., Pinto A.C., Ameye L. et al. The prognostic performance of adjuvant! Online and Nottingham prognostic index in young breast cancer patients. Br J Cancer 2016;115:1471–8.4. Partridge A.H., Hughes M.E., Warner E.T. et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 2016;34:3308–14.Partridge A.H., Hughes M.E., Warner E.T. et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 2016;34:3308–14.5. Senkus E., Kyriakides S., Penault-Llorca F. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi7–vi23.Senkus E., Kyriakides S., Penault-Llorca F. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi7–vi23.6. Burstein H.J., Temin S., Anderson H. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2014;32:2255–69.Burstein H.J., Temin S., Anderson H. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2014;32:2255–69.7. Стенина М.Б., Фролова М.А., Купчан Д.З., Тюляндин С.А. Изменения в нео- и адъювантном лечении рака молочной железы за последние 5 лет. Практическая онкология 2017;18(3):256–64. [Stenina M.B., Frolova M.A., Kupchan D.Z., Tylyandin S.A. Changes in neoadjuvant and adjuvant treatment for breast cancer over the last 5 years. Prakticheskaya onkologiya = Practical Oncology 2017;18(3):256–64. (In Russ.)].Стенина М.Б., Фролова М.А., Купчан Д.З., Тюляндин С.А. Изменения в нео- и адъювантном лечении рака молочной железы за последние 5 лет. Практическая онкология 2017;18(3):256–64. [Stenina M.B., Frolova M.A., Kupchan D.Z., Tylyandin S.A. Changes in neoadjuvant and adjuvant treatment for breast cancer over the last 5 years. Prakticheskaya onkologiya = Practical Oncology 2017;18(3):256–64. (In Russ.)].8. Papakonstantinou A., Foukakis T., Rodriguez Wallberg K.A., Bergh J. Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer? J Clin Oncol 2016;34(14):1573–9.Papakonstantinou A., Foukakis T., Rodriguez Wallberg K.A., Bergh J. Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer? J Clin Oncol 2016;34(14):1573–9.9. Lambertini M., Poggio F., Vaglica M. et al. News on the medical treatment of young women with early-stage HER2-negative breast cancer. Expert Opin Pharmacother 2016;17:1643–55.Lambertini M., Poggio F., Vaglica M. et al. News on the medical treatment of young women with early-stage HER2-negative breast cancer. Expert Opin Pharmacother 2016;17:1643–55.10. Tevaarwerk A.J., Wang M., Zhao F. et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptorpositive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014;32:3948–58.Tevaarwerk A.J., Wang M., Zhao F. et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptorpositive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014;32:3948–58.11. Francis P.A., Regan M.M., Fleming G.F. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372:436–46.Francis P.A., Regan M.M., Fleming G.F. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372:436–46.12. Fleming G., Francis P.A., Láng I. et al. Abstract GS4-03: randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial. Cancer Res 2018;78:GS4–03.Fleming G., Francis P.A., Láng I. et al. Abstract GS4-03: randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial. Cancer Res 2018;78:GS4–03.13. Goldhirsch A., Wood W.C., Gelber R.D. et al. Progress and promise: highlights of the international expert consensus on the primary therapyof early breast cancer 2007. Ann Oncol 2007;18(7):1133–44.Goldhirsch A., Wood W.C., Gelber R.D. et al. Progress and promise: highlights of the international expert consensus on the primary therapyof early breast cancer 2007. Ann Oncol 2007;18(7):1133–44.14. Saha P., Regan M.M., Pagani O. et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol 2017;35:3113–22.Saha P., Regan M.M., Pagani O. et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol 2017;35:3113–22.15. Ribi K., Luo W., Bernhard J. et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 2016;34:1601–10.Ribi K., Luo W., Bernhard J. et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 2016;34:1601–10.16. Burstein H.J., Lacchetti C., Anderson H. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 2016;34:1689–701.Burstein H.J., Lacchetti C., Anderson H. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 2016;34:1689–701.17. Paluch-Shimon S., Pagani O., Partridge A.H. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast 2017;35:203–17.Paluch-Shimon S., Pagani O., Partridge A.H. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast 2017;35:203–17.18. Curigliano G., Burstein H.J., P Winer E. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol 2017;28:1700–12.Curigliano G., Burstein H.J., P Winer E. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol 2017;28:1700–12.19. Gnant M., Mlineritsch B., Stoeger H. et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015;26:313–20.Gnant M., Mlineritsch B., Stoeger H. et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015;26:313–20.20. Pagani O., Regan M.M., Fleming G.F. et al. Abstract GS4-02: randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials. Cancer Res 2018;78:GS4–02.Pagani O., Regan M.M., Fleming G.F. et al. Abstract GS4-02: randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials. Cancer Res 2018;78:GS4–02.21. Regan M.M., Francis P.A, Pagani O. et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials. J Clin Oncol 2016;34:2221–31.Regan M.M., Francis P.A, Pagani O. et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials. J Clin Oncol 2016;34:2221–31.22. Lambertini M. Pooled analysis of five randomized trial investigating temporary ovarian suppression with gonadotropinreleasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients.SABCS-2017. Abstr. GS4–01.Lambertini M. Pooled analysis of five randomized trial investigating temporary ovarian suppression with gonadotropinreleasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients.SABCS-2017. Abstr. GS4–01.23. Lambertini M., Viglietti G., de Azambuja E. Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? ESMO Open 2018;3:e000350. DOI:10.1136/esmoopen-2018-000350.Lambertini M., Viglietti G., de Azambuja E. Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? ESMO Open 2018;3:e000350. DOI:10.1136/esmoopen-2018-000350.24. Стенина М.Б., Жукова Л.Г., Королева И.А и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли 2016;4(Спецвыпуск 2): 97–122. [Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical guidelines for invasive breast cancer chemotherapy. Malignant tumors 2016;4 (special issue 2):97–122. (In Russ.)].Стенина М.Б., Жукова Л.Г., Королева И.А и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли 2016;4(Спецвыпуск 2): 97–122. [Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical guidelines for invasive breast cancer chemotherapy. Malignant tumors 2016;4 (special issue 2):97–122. (In Russ.)].25. Pagani O., Ruggeri M., Manunta S. et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast 2015;24:201–7.Pagani O., Ruggeri M., Manunta S. et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast 2015;24:201–7.